Premium
Intralesional injection of corticosteroid for treatment of central giant cell lesions: case report and literature review
Author(s) -
Oliveira L.J.,
Lehman L.F.C.,
Gomez R.S.,
Castro W.H.
Publication year - 2016
Publication title -
oral surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.156
H-Index - 11
eISSN - 1752-248X
pISSN - 1752-2471
DOI - 10.1111/ors.12161
Subject(s) - medicine , triamcinolone acetonide , corticosteroid , lesion , surgery , lidocaine
We aimed to report a case of a central giant cell lesion in the anterior region of the mandible that was treated by intralesional corticosteroid injections. We also performed a review of the literature related to this condition. The patient was a 37 year‐old woman who was referred to our hospital. Treatment consisted of 10 intralesional injections of Theracort 40 mg/mL (Theraskin Farmacêutica Ltda., São Bernardo do Campo, SP, Brazil) [triamcinolone acetonide (40 mg/mL) suspension; 1 mL] and 2% lidocaine (1.8 mL) with adrenaline (1:100 000 dilution). Injections were administered via a needle (27 gauge, 1/2 inch) at different sites and depths within the lesion every 15 days. The patient was followed up for 32 months. Complete healing of the lesion was confirmed by clinical examination and imaging. No evidence of recurrence or side effects related to the corticosteroid treatment was noted. Intralesional injections of corticosteroids should be considered as an alternative to surgery. Such therapy is simple, less aggressive and less expensive, and avoids the aesthetic and functional damage associated with aggressive surgical treatment.